Significant New Treatment Advances in DLBCL.

Published Date: 20 May 2023

The use of CAR T-cell and immunotherapies, as well as the FDA's approval of polatuzumab for frontline DLBCL, have led to recent significant advancements in the treatment of diffuse large B-cell lymphoma (DLBCL).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot